A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
Identifieur interne : 000E80 ( Main/Exploration ); précédent : 000E79; suivant : 000E81A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
Auteurs : Ali A. Rabaan [Arabie saoudite] ; Shamsah H. Alahmed [Arabie saoudite] ; Ali M. Bazzi [Arabie saoudite] ; Hatem M. Alhani [Arabie saoudite]Source :
- Journal of medical microbiology [ 1473-5644 ] ; 2017.
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Cathepsine L (antagonistes et inhibiteurs), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (génétique), Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Humains, Infections à coronavirus (), Infections à coronavirus (virologie), Inhibiteurs de la sérine protéinase (usage thérapeutique), Interactions hôte-pathogène, Interférons (usage thérapeutique), Serine endopeptidases (métabolisme), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (usage thérapeutique), Études prospectives.
- MESH :
- administration et posologie : Vaccins antiviraux.
- antagonistes et inhibiteurs : Cathepsine L.
- génétique : Coronavirus du syndrome respiratoire du Moyen-Orient.
- isolement et purification : Coronavirus du syndrome respiratoire du Moyen-Orient.
- métabolisme : Serine endopeptidases.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- usage thérapeutique : Antiviraux, Inhibiteurs de la sérine protéinase, Interférons, Vaccins antiviraux.
- virologie : Infections à coronavirus.
- Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Infections à coronavirus, Interactions hôte-pathogène, Études prospectives.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Cathepsin L (antagonists & inhibitors), Coronavirus Infections (therapy), Coronavirus Infections (virology), Host-Pathogen Interactions, Humans, Interferons (therapeutic use), Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (isolation & purification), Middle East Respiratory Syndrome Coronavirus (physiology), Prospective Studies, Serine Endopeptidases (metabolism), Serine Proteinase Inhibitors (therapeutic use), Viral Vaccines (administration & dosage), Viral Vaccines (therapeutic use).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , antagonists & inhibitors : Cathepsin L.
- chemical , metabolism : Serine Endopeptidases.
- chemical , therapeutic use : Antiviral Agents, Interferons, Serine Proteinase Inhibitors, Viral Vaccines.
- drug effects : Middle East Respiratory Syndrome Coronavirus.
- genetics : Middle East Respiratory Syndrome Coronavirus.
- isolation & purification : Middle East Respiratory Syndrome Coronavirus.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- therapy : Coronavirus Infections.
- virology : Coronavirus Infections.
- Host-Pathogen Interactions, Humans, Prospective Studies.
Abstract
There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, including broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir or mycophenolate mofetil, and have not been subject to well-organized clinical trials. The development of specific therapies and vaccines is therefore urgently required. We examine existing and potential therapies and vaccines from a molecular perspective. These include viral S protein targeting; inhibitors of host proteases, including TMPRSS2, cathepsin L and furin protease, and of viral M(pro) and the PL(pro) proteases; convalescent plasma; and vaccine candidates. The Medline database was searched using combinations and variations of terms, including 'Middle East respiratory syndrome coronavirus', 'MERS-CoV', 'SARS', 'therapy', 'molecular', 'vaccine', 'prophylactic', 'S protein', 'DPP4', 'heptad repeat', 'protease', 'inhibitor', 'anti-viral', 'broad-spectrum', 'interferon', 'convalescent plasma', 'lopinavir ritonavir', 'antibodies', 'antiviral peptides' and 'live attenuated viruses'. There are many options for the development of MERS-CoV-specific therapies. Currently, MERS-CoV is not considered to have pandemic potential. However, the high mortality rate and potential for mutations that could increase transmissibility give urgency to the search for direct, effective therapies. Well-designed and controlled clinical trials are needed, both for existing therapies and for prospective direct therapies.
DOI: 10.1099/jmm.0.000565
PubMed: 28855003
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A84
- to stream PubMed, to step Curation: 000A84
- to stream PubMed, to step Checkpoint: 000B60
- to stream Ncbi, to step Merge: 002E43
- to stream Ncbi, to step Curation: 002E43
- to stream Ncbi, to step Checkpoint: 002E43
- to stream Main, to step Merge: 000E82
- to stream Main, to step Curation: 000E80
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.</title><author><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alahmed, Shamsah H" sort="Alahmed, Shamsah H" uniqKey="Alahmed S" first="Shamsah H" last="Alahmed">Shamsah H. Alahmed</name><affiliation wicri:level="1"><nlm:affiliation>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654</wicri:regionArea><wicri:noRegion>Qatif 32654</wicri:noRegion></affiliation></author><author><name sortKey="Bazzi, Ali M" sort="Bazzi, Ali M" uniqKey="Bazzi A" first="Ali M" last="Bazzi">Ali M. Bazzi</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alhani, Hatem M" sort="Alhani, Hatem M" uniqKey="Alhani H" first="Hatem M" last="Alhani">Hatem M. Alhani</name><affiliation wicri:level="1"><nlm:affiliation>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam</wicri:regionArea><wicri:noRegion>Dammam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28855003</idno><idno type="pmid">28855003</idno><idno type="doi">10.1099/jmm.0.000565</idno><idno type="wicri:Area/PubMed/Corpus">000A84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A84</idno><idno type="wicri:Area/PubMed/Curation">000A84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A84</idno><idno type="wicri:Area/PubMed/Checkpoint">000B60</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B60</idno><idno type="wicri:Area/Ncbi/Merge">002E43</idno><idno type="wicri:Area/Ncbi/Curation">002E43</idno><idno type="wicri:Area/Ncbi/Checkpoint">002E43</idno><idno type="wicri:Area/Main/Merge">000E82</idno><idno type="wicri:Area/Main/Curation">000E80</idno><idno type="wicri:Area/Main/Exploration">000E80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.</title><author><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alahmed, Shamsah H" sort="Alahmed, Shamsah H" uniqKey="Alahmed S" first="Shamsah H" last="Alahmed">Shamsah H. Alahmed</name><affiliation wicri:level="1"><nlm:affiliation>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654</wicri:regionArea><wicri:noRegion>Qatif 32654</wicri:noRegion></affiliation></author><author><name sortKey="Bazzi, Ali M" sort="Bazzi, Ali M" uniqKey="Bazzi A" first="Ali M" last="Bazzi">Ali M. Bazzi</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alhani, Hatem M" sort="Alhani, Hatem M" uniqKey="Alhani H" first="Hatem M" last="Alhani">Hatem M. Alhani</name><affiliation wicri:level="1"><nlm:affiliation>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam</wicri:regionArea><wicri:noRegion>Dammam</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of medical microbiology</title><idno type="eISSN">1473-5644</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Cathepsin L (antagonists & inhibitors)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Host-Pathogen Interactions</term><term>Humans</term><term>Interferons (therapeutic use)</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Middle East Respiratory Syndrome Coronavirus (genetics)</term><term>Middle East Respiratory Syndrome Coronavirus (isolation & purification)</term><term>Middle East Respiratory Syndrome Coronavirus (physiology)</term><term>Prospective Studies</term><term>Serine Endopeptidases (metabolism)</term><term>Serine Proteinase Inhibitors (therapeutic use)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Cathepsine L (antagonistes et inhibiteurs)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (virologie)</term><term>Inhibiteurs de la sérine protéinase (usage thérapeutique)</term><term>Interactions hôte-pathogène</term><term>Interférons (usage thérapeutique)</term><term>Serine endopeptidases (métabolisme)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cathepsin L</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Serine Endopeptidases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferons</term><term>Serine Proteinase Inhibitors</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cathepsine L</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Serine endopeptidases</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de la sérine protéinase</term><term>Interférons</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Host-Pathogen Interactions</term><term>Humans</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term><term>Infections à coronavirus</term><term>Interactions hôte-pathogène</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, including broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir or mycophenolate mofetil, and have not been subject to well-organized clinical trials. The development of specific therapies and vaccines is therefore urgently required. We examine existing and potential therapies and vaccines from a molecular perspective. These include viral S protein targeting; inhibitors of host proteases, including TMPRSS2, cathepsin L and furin protease, and of viral M(pro) and the PL(pro) proteases; convalescent plasma; and vaccine candidates. The Medline database was searched using combinations and variations of terms, including 'Middle East respiratory syndrome coronavirus', 'MERS-CoV', 'SARS', 'therapy', 'molecular', 'vaccine', 'prophylactic', 'S protein', 'DPP4', 'heptad repeat', 'protease', 'inhibitor', 'anti-viral', 'broad-spectrum', 'interferon', 'convalescent plasma', 'lopinavir ritonavir', 'antibodies', 'antiviral peptides' and 'live attenuated viruses'. There are many options for the development of MERS-CoV-specific therapies. Currently, MERS-CoV is not considered to have pandemic potential. However, the high mortality rate and potential for mutations that could increase transmissibility give urgency to the search for direct, effective therapies. Well-designed and controlled clinical trials are needed, both for existing therapies and for prospective direct therapies.</div></front></TEI><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name></noRegion><name sortKey="Alahmed, Shamsah H" sort="Alahmed, Shamsah H" uniqKey="Alahmed S" first="Shamsah H" last="Alahmed">Shamsah H. Alahmed</name><name sortKey="Alhani, Hatem M" sort="Alhani, Hatem M" uniqKey="Alhani H" first="Hatem M" last="Alhani">Hatem M. Alhani</name><name sortKey="Bazzi, Ali M" sort="Bazzi, Ali M" uniqKey="Bazzi A" first="Ali M" last="Bazzi">Ali M. Bazzi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28855003
|texte= A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28855003" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |